Drug profile · INN
terazosin hydrochloride
TERAZOSIN HYDROCHLORIDE
terazosin hydrochloride (TERAZOSIN HYDROCHLORIDE) is a adrenergic receptor alpha-1 antagonist. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Drug details — terazosin hydrochloride
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 1
- Programs
- 1
- Data quality
- 0.89
Quick answer
terazosin hydrochloride (TERAZOSIN HYDROCHLORIDE) is a adrenergic receptor alpha-1 antagonist. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Adrenergic receptor alpha-1 antagonist
Primary target: Adrenergic receptor alpha-1
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is terazosin hydrochloride?
terazosin hydrochloride (TERAZOSIN HYDROCHLORIDE) is a adrenergic receptor alpha-1 antagonist. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for terazosin hydrochloride?
TERAZOSIN HYDROCHLORIDE is a marketed brand name for terazosin hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of terazosin hydrochloride?
terazosin hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.